Why trial data gaps matter for women: what the record shows and what patients can ask

Why trial data gaps matter for women: what the record shows and what patients can ask

Clinical trial transparency and complete demographic data are often discussed as abstract principles. For women and people who menstruate, however, gaps in how sex and gender are collected, analyzed and reported can have direct consequences for diagnosis, treatment choices and informed consent. Recent audits of trial reporting, parallel shifts in U.S. regulatory expectations, and new methodological guidance help clarify the problem — and what participants and clinicians should look for when evaluating trials.

What the empirical record reveals

A systematic curation of oncology interventional trials found that only 472 of 89,221 trials (about 0.5%) reported post‑treatment statistical comparisons between males and females, and that when comparisons were curated, 66.9% showed sex differences in outcomes or toxicity patterns ^[1]. That pattern — sparse direct sex‑comparison reporting but frequent differences when comparisons are made — is a practical concern: without routine, prespecified analyses and complete demographic data, clinicians and patients lack reliable subgroup information to weigh benefits and harms.

Separately, institutional monitoring of federally funded research shows continuing problems with incomplete demographic fields. Triennial NIH inclusion monitoring reports for FY2022–FY2024 document uneven completeness (including a sizable share of records with “unknown” for some demographics) and variable female representation across some portfolios, which limits the ability to perform robust sex‑by‑treatment analyses ^[2].

Regulatory momentum — and its limits

The U.S. Food and Drug Administration has signalled increased attention to sex and gender in clinical evaluation. Draft guidances announced in early 2025 include documents on sex‑ and gender‑specific data for medical devices and studying sex differences in clinical evaluations; and a 2024 draft on Diversity Action Plans (DAPs) under FDORA would require sponsors to state enrollment goals disaggregated by age, sex and race/ethnicity and describe strategies and monitoring for meeting those goals ^[3][4].

These documents mark a convergence of expectations: sponsors should plan for and report on sex‑disaggregated enrollment and analyses. But several practical caveats remain. The DAP guidance was published as a draft and flagged as not for implementation until finalized; the actual content of final guidances, timelines for compliance, and how agencies will assess the adequacy of sex‑specific plans are still evolving. Legal and industry analyses also highlight operational challenges for sponsors — setting justifiable, clinically informed sex‑specific enrollment goals, monitoring progress, and managing sites and recruitment logistics without unduly delaying trials [8].

Why methodological guidance matters

Method papers and checklists provide concrete routes to improvement but also underscore limits. A recent interdisciplinary checklist for quantitative health research recommends bringing multidimensional sex/gender concepts and intersectionality into study design, analysis and dissemination — moving beyond binary categories where appropriate — but notes complexity and the need for expert input to operationalize these items in real studies ^[5]. Practical best‑practice discussions in physiological research similarly recommend clear definitions (sex vs. gender), prespecified power plans for sex comparisons and transparent reporting, while acknowledging logistical and statistical barriers investigators face ^[6].

Practical implications for patients and clinicians

• Before joining a trial: ask whether enrollment goals for sex (and other relevant demographics) were prespecified and whether the protocol includes planned sex‑disaggregated analyses. If a sponsor has filed a Diversity Action Plan or similar document, ask whether it is public and what monitoring milestones it uses ^[3][4].
• When reviewing consent materials: look for explicit language on subgroup analyses and what will be reported back to participants. If materials are silent about sex‑specific reporting, that is a reasonable question for the study team.
• For clinicians advising patients: request trial‑level demographic tables and any available subgroup results; when data are unavailable, note the uncertainty when discussing expected benefits and harms for women and patients of other sex/gender groups.
• For patients after a trial: ask whether summary results will include sex‑disaggregated outcomes and where to find them (clinicaltrials.gov results, sponsor websites, or peer‑reviewed publications).

Limitations and remaining uncertainties

Two linked limitations temper immediate expectation of comprehensive change. First, even with new guidance, implementing prespecified sex analyses requires sufficient enrollment of each group and appropriate statistical plans; many trials remain underpowered for reliable sex‑by‑treatment interaction testing ^[6]. Second, administrative reports and audits document data completeness problems that must be fixed before large‑scale subgroup analyses become routine ^[2].

That said, the convergence of empirical audits showing sparse sex comparisons, draft regulatory expectations for disaggregated planning and reporting, and methodological tools for operationalizing sex/gender considerations creates a clearer pathway. For clinicians and patients, the immediate, practical step is greater insistence on transparency: asking whether sex was considered during trial design, how enrollment was planned and monitored, and where sex‑disaggregated results will be posted.

Greater transparency will not eliminate uncertainty overnight, but it will make clear where evidence applies — and where caution is warranted for women and people who menstruate when translating trial findings into clinical care.

Key sources: Nature Communications systematic curation of oncology trials; FDA draft Diversity Action Plan guidance (June 2024) and FDA Roundup noting draft sex/gender guidances (Jan 2025); NIH inclusion monitoring reports (FY2022–FY2024); methodological checklists and best practices literature.